Novavax (NVAX) Stock Forecast, Price Target & Predictions
NVAX Stock Forecast
Novavax stock forecast is as follows: an average price target of $74.67 (represents a 542.05% upside from NVAX’s last price of $11.63) and a rating consensus of 'Buy', based on 18 wall street analysts offering a 1-year stock forecast.
NVAX Price Target
The average price target for Novavax (NVAX) is $74.67 based on 1-year price targets from 18 Wall Street analysts in the past 3 months, with a price target range of $174.00 to $19.00. This represents a potential 542.05% upside from NVAX's last price of $11.63.
NVAX Analyst Ratings
According to 18 Wall Street analysts, Novavax's rating consensus is 'Buy'. The analyst rating breakdown for NVAX stock is 0 'Strong Buy' (0.00%), 9 'Buy' (50.00%), 8 'Hold' (44.44%), 1 'Sell' (5.56%), and 0 'Strong Sell' (0.00%).
Novavax Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jul 19, 2024 | Roger Song | Jefferies | $31.00 | $14.36 | 115.88% | 166.55% |
| May 10, 2024 | Vernon Bernardino | H.C. Wainwright | $19.00 | $9.94 | 91.24% | 63.37% |
| Feb 14, 2022 | Charles Duncan | Cantor Fitzgerald | $174.00 | $80.11 | 117.20% | 1396.13% |
The latest Novavax stock forecast, released on Jul 19, 2024 by Roger Song from Jefferies, set a price target of $31.00, which represents a 115.88% increase from the stock price at the time of the forecast ($14.36), and a 166.55% increase from NVAX last price ($11.63).
Novavax Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 2 |
| Avg Price Target | - | $31.00 | $25.00 |
| Last Closing Price | $11.63 | $11.63 | $11.63 |
| Upside/Downside | -100.00% | 166.55% | 114.96% |
In the current month, the average price target of Novavax stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Novavax's last price of $11.63. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jul 19, 2024 | Jefferies | Buy | Buy | Hold |
| May 23, 2024 | B. Riley | Buy | Buy | Hold |
| May 13, 2024 | Cowen & Co. | Hold | Hold | Hold |
| May 10, 2024 | Bank of America Securities | Underperform | Neutral | Upgrade |
| May 10, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 09, 2023 | RBC Capital | - | Sector Perform | Downgrade |
| Aug 09, 2023 | Raymond James | Market Perform | Outperform | Upgrade |
| Aug 09, 2023 | Wells Fargo | - | Overweight | Upgrade |
| Aug 09, 2023 | Evercore ISI | - | Neutral | Downgrade |
| Aug 09, 2023 | Telsey Advisory | - | Market Perform | Downgrade |
Novavax's last stock rating was published by Jefferies on Jul 19, 2024. The company gave NVAX a "Buy" rating, the same as its previous rate.
Novavax Financial Forecast
Novavax Revenue Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | Mar 15 | Mar 14 | Mar 13 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | $186.99M | $424.43M | $80.95M | $287.83M | $734.58M | $185.93M | $703.97M | $222.20M | $178.84M | $298.02M | $447.23M | $279.66M | $157.02M | $35.54M | $3.38M | $8.82M | $2.51M | $3.36M | $3.98M | $9.65M | $5.68M | $4.22M | $9.88M | $7.46M | $3.83M |
| Avg Forecast | $168.07M | $59.03M | $458.57M | $101.16M | $322.05M | $115.42M | $264.16M | $87.61M | $383.14M | $586.25M | $863.68M | $845.20M | $331.79M | $334.53M | $387.87M | $233.90M | $202.44M | $230.56M | $28.20M | $1.93M | $2.06M | $2.66M | $3.06M | $4.42M | $9.24M | $6.04M | $3.93M | $10.87M | $7.67M | $3.12M |
| High Forecast | $343.56M | $145.71M | $937.40M | $206.79M | $363.50M | $235.94M | $539.98M | $179.10M | $783.21M | $1.20B | $1.95B | $1.91B | $749.32M | $755.52M | $875.98M | $528.24M | $457.18M | $520.69M | $63.69M | $4.36M | $4.66M | $6.00M | $6.92M | $9.98M | $11.08M | $7.24M | $4.71M | $13.04M | $9.21M | $3.74M |
| Low Forecast | $37.87M | $16.05M | $103.32M | $22.79M | $290.31M | $26.00M | $59.52M | $19.74M | $86.32M | $132.09M | $277.72M | $271.77M | $106.69M | $107.57M | $124.72M | $75.21M | $65.09M | $74.14M | $9.07M | $621.11K | $663.13K | $853.97K | $985.39K | $1.42M | $7.39M | $4.83M | $3.14M | $8.69M | $6.14M | $2.49M |
| # Analysts | 2 | 4 | 2 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 10 | 16 | 8 | 11 | 7 | 11 | 7 | 7 | 17 | 9 | 12 | 16 | 20 | 19 |
| Surprise % | - | - | - | - | - | 1.62% | 1.61% | 0.92% | 0.75% | 1.25% | 0.22% | 0.83% | 0.67% | 0.53% | 0.77% | 1.91% | 1.38% | 0.68% | 1.26% | 1.75% | 4.27% | 0.94% | 1.10% | 0.90% | 1.05% | 0.94% | 1.07% | 0.91% | 0.97% | 1.23% |
Novavax's average Quarter revenue forecast for Dec 23 based on 5 analysts is $322.05M, with a low forecast of $290.31M, and a high forecast of $363.50M. NVAX's average Quarter revenue forecast represents a 72.23% increase compared to the company's last Quarter revenue of $186.99M (Sep 23).
Novavax EBITDA Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | Mar 15 | Mar 14 | Mar 13 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 4 | 2 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 10 | 16 | 8 | 11 | 7 | 11 | 7 | 7 | 17 | 9 | 12 | 16 | 20 | 19 |
| EBITDA | - | - | - | - | - | $-125.63M | $55.46M | $-279.36M | $-179.91M | $-153.63M | $-496.11M | $217.35M | $-820.87M | $-306.95M | $-340.39M | $-212.55M | $-170.82M | $-192.02M | $-13.49M | $-21.89M | $-27.85M | $-14.12M | $-34.63M | $-38.23M | $-41.23M | $-38.23M | $-72.87M | $-23.02M | $-12.78M | $-9.51M |
| Avg Forecast | $-122.77M | $-43.12M | $-334.99M | $-73.90M | $-235.26M | $-84.32M | $-192.97M | $-64.00M | $-279.89M | $-315.08M | $-630.93M | $227.86M | $-242.38M | $-244.38M | $-283.35M | $-245.02M | $-147.88M | $-168.42M | $-20.60M | $-25.64M | $-1.51M | $-1.94M | $-2.24M | $-38.40M | $-39.38M | $-40.48M | $-67.47M | $-25.12M | $-13.13M | $-7.34M |
| High Forecast | $-27.66M | $-11.72M | $-75.48M | $-16.65M | $-212.07M | $-19.00M | $-43.48M | $-14.42M | $-63.06M | $-252.06M | $-202.88M | $273.43M | $-77.94M | $-78.58M | $-91.11M | $-196.01M | $-47.55M | $-54.16M | $-6.62M | $-20.52M | $-484.42K | $-623.84K | $-719.84K | $-30.72M | $-31.50M | $-32.38M | $-53.98M | $-20.09M | $-10.51M | $-5.87M |
| Low Forecast | $-250.97M | $-106.44M | $-684.78M | $-151.06M | $-265.54M | $-172.36M | $-394.46M | $-130.83M | $-572.14M | $-378.09M | $-1.42B | $182.29M | $-547.39M | $-551.91M | $-639.91M | $-294.02M | $-333.98M | $-380.37M | $-46.52M | $-30.77M | $-3.40M | $-4.38M | $-5.06M | $-46.09M | $-47.26M | $-48.57M | $-80.96M | $-30.14M | $-15.76M | $-8.81M |
| Surprise % | - | - | - | - | - | 1.49% | -0.29% | 4.36% | 0.64% | 0.49% | 0.79% | 0.95% | 3.39% | 1.26% | 1.20% | 0.87% | 1.16% | 1.14% | 0.66% | 0.85% | 18.49% | 7.28% | 15.47% | 1.00% | 1.05% | 0.94% | 1.08% | 0.92% | 0.97% | 1.30% |
4 analysts predict NVAX's average Quarter EBITDA for Sep 23 to be $-84.32M, with a high of $-19.00M and a low of $-172.36M. This is -252.04% lower than Novavax's previous annual EBITDA (Jun 23) of $55.46M.
Novavax Net Income Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | Mar 15 | Mar 14 | Mar 13 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 4 | 2 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 10 | 16 | 8 | 11 | 7 | 11 | 7 | 7 | 17 | 9 | 12 | 16 | 20 | 19 |
| Net Income | - | - | - | - | - | $-130.78M | $58.01M | $-293.90M | $-182.25M | $-168.61M | $-510.49M | $203.41M | $-846.28M | $-322.43M | $-352.32M | $-222.72M | $-177.56M | $-197.31M | $-17.52M | $-25.86M | $-31.83M | $-18.04M | $-39.60M | $-43.22M | $-46.35M | $-43.85M | $-77.25M | $-24.37M | $-13.81M | $-10.00M |
| Avg Forecast | $-50.86M | $-149.82M | $276.98M | $258.02M | $-74.30M | $-367.37M | $-220.86M | $234.56M | $-168.18M | $-330.97M | $604.26M | $213.24M | $-298.87M | $-647.99M | $-602.39M | $-256.75M | $-369.30M | $287.15M | $-83.92M | $-30.30M | $-176.04M | $-128.37M | $-265.07M | $-43.41M | $-44.28M | $-46.43M | $-71.53M | $-26.59M | $-14.19M | $-7.72M |
| High Forecast | $361.25K | $-78.32M | $652.95M | $309.62M | $12.13M | $2.61M | $1.57M | $281.47M | $1.19M | $-264.78M | $1.59B | $255.89M | $-35.27M | $-76.47M | $-71.09M | $-205.40M | $-43.58M | $756.90M | $-9.90M | $-24.24M | $-20.78M | $-15.15M | $-31.28M | $-34.73M | $-35.42M | $-37.15M | $-57.22M | $-21.27M | $-11.35M | $-6.17M |
| Low Forecast | $-119.90M | $-200.90M | $-1.97M | $206.41M | $-195.61M | $-866.04M | $-520.67M | $187.65M | $-396.46M | $-397.16M | $71.31M | $170.59M | $-787.80M | $-1.71B | $-1.59B | $-308.09M | $-973.46M | $33.89M | $-221.21M | $-36.36M | $-464.04M | $-338.38M | $-698.70M | $-52.10M | $-53.13M | $-55.72M | $-85.84M | $-31.90M | $-17.03M | $-9.26M |
| Surprise % | - | - | - | - | - | 0.36% | -0.26% | -1.25% | 1.08% | 0.51% | -0.84% | 0.95% | 2.83% | 0.50% | 0.58% | 0.87% | 0.48% | -0.69% | 0.21% | 0.85% | 0.18% | 0.14% | 0.15% | 1.00% | 1.05% | 0.94% | 1.08% | 0.92% | 0.97% | 1.30% |
Novavax's average Quarter net income forecast for Sep 23 is $-367.37M, with a range of $-866.04M to $2.61M. NVAX's average Quarter net income forecast represents a -733.31% decrease compared to the company's last Quarter net income of $58.01M (Jun 23).
Novavax SG&A Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | Mar 15 | Mar 14 | Mar 13 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 4 | 2 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 10 | 16 | 8 | 11 | 7 | 11 | 7 | 7 | 17 | 9 | 12 | 16 | 20 | 19 |
| SG&A | - | - | - | - | - | $107.46M | $93.72M | $112.53M | $161.66M | $122.88M | $108.16M | $95.99M | $84.21M | $77.79M | $73.16M | $63.19M | $61.31M | $56.88M | $17.72M | $9.38M | $8.18M | $7.90M | $9.61M | $8.73M | $8.65M | $8.85M | $10.53M | $5.84M | $4.31M | $2.69M |
| Avg Forecast | $106.90M | $37.55M | $291.69M | $64.35M | $204.85M | $73.42M | $168.02M | $55.73M | $243.71M | $79.85M | $549.37M | $100.63M | $211.04M | $212.79M | $246.72M | $72.84M | $128.76M | $146.65M | $17.94M | $1.23M | $1.31M | $1.69M | $1.95M | $2.81M | $8.26M | $3.84M | $2.50M | $6.37M | $4.43M | $2.08M |
| High Forecast | $218.53M | $92.68M | $596.26M | $131.53M | $231.21M | $150.07M | $343.47M | $113.92M | $498.18M | $95.82M | $1.24B | $120.76M | $476.62M | $480.56M | $557.19M | $87.41M | $290.80M | $331.20M | $40.51M | $2.77M | $2.96M | $3.82M | $4.40M | $6.35M | $9.92M | $4.61M | $3.00M | $7.65M | $5.31M | $2.50M |
| Low Forecast | $24.09M | $10.21M | $65.72M | $14.50M | $184.66M | $16.54M | $37.86M | $12.56M | $54.91M | $63.88M | $176.65M | $80.50M | $67.86M | $68.42M | $79.33M | $58.28M | $41.40M | $47.16M | $5.77M | $395.07K | $421.80K | $543.19K | $626.78K | $903.57K | $6.61M | $3.07M | $2.00M | $5.10M | $3.54M | $1.66M |
| Surprise % | - | - | - | - | - | 1.46% | 0.56% | 2.02% | 0.66% | 1.54% | 0.20% | 0.95% | 0.40% | 0.37% | 0.30% | 0.87% | 0.48% | 0.39% | 0.99% | 7.63% | 6.24% | 4.68% | 4.93% | 3.11% | 1.05% | 2.31% | 4.21% | 0.92% | 0.97% | 1.30% |
Novavax's average Quarter SG&A projection for Dec 23 is $204.85M, based on 5 Wall Street analysts, with a range of $184.66M to $231.21M. The forecast indicates a 90.63% rise compared to NVAX last annual SG&A of $107.46M (Sep 23).
Novavax EPS Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | Mar 15 | Mar 14 | Mar 13 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 4 | 2 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 10 | 16 | 8 | 11 | 7 | 11 | 7 | 7 | 17 | 9 | 12 | 16 | 20 | 19 |
| EPS | - | - | - | - | - | $-1.26 | $0.65 | $-3.41 | $-2.28 | $-2.15 | $-6.53 | $2.66 | $-11.18 | $-4.31 | $-4.75 | $-3.05 | $-2.70 | $-3.21 | $-0.30 | $-0.58 | $-1.13 | $-0.74 | $-1.69 | $-2.20 | $-2.80 | $-3.20 | $-5.80 | $-2.00 | $-1.40 | $-1.40 |
| Avg Forecast | $-0.31 | $-0.90 | $1.67 | $-1.06 | $-0.45 | $-2.21 | $-1.33 | $-3.46 | $-1.01 | $1.57 | $3.64 | $2.69 | $-1.80 | $-3.91 | $-3.63 | $-3.60 | $-2.23 | $1.73 | $-0.51 | $-0.69 | $-1.06 | $-0.77 | $-1.60 | $-2.13 | $-2.56 | $-0.18 | $-0.25 | $-0.12 | $-1.48 | $-0.88 |
| High Forecast | - | $-0.47 | $3.94 | $0.01 | $0.07 | $0.02 | $0.01 | $0.02 | $0.01 | $3.70 | $9.60 | $7.09 | $-0.21 | $-0.46 | $-0.43 | $-0.42 | $-0.26 | $4.56 | $-0.06 | $-0.08 | $-0.13 | $-0.09 | $-0.19 | $-0.25 | $-2.05 | $-0.14 | $-0.20 | $-0.10 | $-1.18 | $-0.70 |
| Low Forecast | $-0.72 | $-1.21 | $-0.01 | $-2.51 | $-1.18 | $-5.22 | $-3.14 | $-8.16 | $-2.39 | $-0.01 | $0.43 | $0.32 | $-4.75 | $-10.30 | $-9.57 | $-9.48 | $-5.87 | $0.20 | $-1.33 | $-1.82 | $-2.80 | $-2.04 | $-4.21 | $-5.62 | $-3.07 | $-0.22 | $-0.30 | $-0.14 | $-1.78 | $-1.06 |
| Surprise % | - | - | - | - | - | 0.57% | -0.49% | 0.98% | 2.25% | -1.37% | -1.79% | 0.99% | 6.20% | 1.10% | 1.31% | 0.85% | 1.21% | -1.85% | 0.59% | 0.84% | 1.06% | 0.96% | 1.06% | 1.03% | 1.09% | 17.78% | 23.20% | 16.67% | 0.95% | 1.59% |
According to 4 Wall Street analysts, Novavax's projected average Quarter EPS for Sep 23 is $-2.21, with a low estimate of $-5.22 and a high estimate of $0.02. This represents a -440.77% decrease compared to NVAX previous annual EPS of $0.65 (Jun 23).
Novavax Peer Comparison by Price Target
NVAX Forecast FAQ
Is Novavax a good buy?
Yes, according to 18 Wall Street analysts, Novavax (NVAX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 9 'Buy' recommendations, accounting for 50.00% of NVAX's total ratings.
What is NVAX's price target?
Novavax (NVAX) average price target is $74.67 with a range of $19 to $174, implying a 542.05% from its last price of $11.63. The data is based on 18 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Novavax stock go up soon?
According to Wall Street analysts' prediction for NVAX stock, the company can go up by 542.05% (from the last price of $11.63 to the average price target of $74.67), up by 1396.13% based on the highest stock price target, and up by 63.37% based on the lowest stock price target.
Can Novavax stock reach $20?
NVAX's average twelve months analyst stock price target of $74.67 supports the claim that Novavax can reach $20 in the near future.
What are Novavax's analysts' financial forecasts?
NVAX's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $786.84M (high $1.63B, low $180.02M), average EBITDA is $-575M (high $-132M, low $-1.193B), average net income is $334.31M (high $884.62M, low $-116M), average SG&A $500.48M (high $1.04B, low $114.51M), and average EPS is $-0.604 (high $3.47, low $-4.454).
Did the NVAX's actual financial results beat the analysts' financial forecasts?
Based on Novavax's last annual report (Dec 2023), the company's revenue was $983.7M, beating the average analysts forecast of $789.24M by 24.64%. Apple's EBITDA was $-567M, missing the average prediction of $-577M by -1.74%. The company's net income was $-545M, beating the average estimation of $-428M by 27.36%. Apple's SG&A was $468.95M, missing the average forecast of $502.02M by -6.59%. Lastly, the company's EPS was $-5.41, missing the average prediction of $-7.457 by -27.45%. In terms of the last quarterly report (Sep 2023), Novavax's revenue was $186.99M, beating the average analysts' forecast of $115.42M by 62.00%. The company's EBITDA was $-126M, beating the average prediction of $-84.316M by 49.00%. Novavax's net income was $-131M, missing the average estimation of $-367M by -64.40%. The company's SG&A was $107.46M, beating the average forecast of $73.42M by 46.37%. Lastly, the company's EPS was $-1.26, missing the average prediction of $-2.215 by -43.12%